Gene-activation mechanisms in the regression of atherosclerosis, elimination of diabetes type 2, and prevention of dementia

Current Molecular Medicine

Volumn 11, Issue 5, 2011, Pages 391-400

  Luoma, P V ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Atherosclerosis; Cyp; Dementia; Diabetes; Endoplasmic reticulum; Gene activation; HDL; LXR

Indexed keywords

16ALPHA CYANOPREGNENOLONE; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; [2 METHYL 4 [4 METHYL 2 (4 TRIFLUOROMETHYLPHENYL) 5 THIAZOLYLMETHYLTHIO]PHENOXY]ACETIC ACID; ABC TRANSPORTER; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A1; ARYLBUTYRIC ACID DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CELL NUCLEUS RECEPTOR; CYTOCHROME P450; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCOKINASE; GW 4046; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER ENZYME; LIVER X RECEPTOR AGONIST; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; NICOTINIC ACID; PHENOBARBITAL; PHENYTOIN; PHOSPHOLIPID; RESIN; RIFAMPICIN; TAUROURSODEOXYCHOLIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; XENOBIOTIC AGENT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ATHEROSCLEROSIS; BIOSYNTHESIS; CELL REGENERATION; CELL STRESS; CELL SURVIVAL; COGNITIVE DEFECT; DEMENTIA; DRUG MECHANISM; ENDOPLASMIC RETICULUM; ENZYME ACTIVATION; GENE ACTIVATION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER LEVEL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN METABOLISM; REVIEW;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CYTOCHROME P-450 ENZYME SYSTEM; DEMENTIA; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; LIVER; MICE; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 79959302999     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411795976556     Document Type: Review

References (102)

1. Bonow RO, Smaha LA, Smith SC Jr, Mensah GA, Lenfant C. The international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002; 106: 1602-5.
2. Brown MT, LeRoith D. Overcoming challenges in type 2 diabetes management to improve patient outcomes. Expert Rev Endocrinol Metab 2010; 5: 741-51.
3. Cornier, M-A, Dabelea D, Hernandez TL, et al. The metabolic syndrome. Endocr Revs 2008; 29: 777-822.
4. Grundy SM. Metabolic syndrome pandemic. Arteriocler Thromb Vasc Biol 2008; 28: 629-36.
5. Luoma PV, Sotaniemi EA, Pelkonen RO, Ehnholm C. Plasma high density lipoprotein and liver microsomal enzyme activity in man. In: The Medical Research Council 1977-1979; Pilli-Sihvola AS, Laaksovirta T, Eds. Helsinki: The Academy of Finland 1980. p. 71.
6. Luoma PV. Gene activation, apolipoprotein A-I/ high density lipoprotein, atherosclerosis prevention and longevity. Pharmacol Toxicol 1997; 81: 57-64.
7. Sotaniemi EA, Arranto AJ, Sutinen S, Stengård JH, Sutinen Sirkka. Treatment of noninsulin-dependent diabetes mellitus with enzyme inducers. Clin Pharmacol Ther 1983; 33: 826-835.
8. Lahtela JT, Arranto AJ, Sotaniemi EA. Enzyme inducers improve insulin sensitivity in non-insulin-dependent diabetic subjects. Diabetes 1985; 34: 911-6.
9. Zelcer N, Khanlou N, Clare R, et al. Attenuation of neuroinflam-mation and Alzheimer's disease pathology by liver X receptors. PNAS 2007; 104: 10601-6.
10. Koldamova R, Fitz NF, Lefterov I. The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration. Biochim Biophys Acta 2010; 1801: 824-830.
11. Ritchie K, Carrière I, Ritchie CW, et al. Designing prevention programmes to reduce of dementia: prospective cohort study of modifiable risk factors. BMJ 2010; 341: c3885.
12. Luoma PV. Enzyme induction, lipids and apolipoproteins. In: Enzyme Induction in Man; Sotaniemi EA, Pelkonen RO, Eds. London: Francis & Taylor 1987; pp. 231-42.
13. Mandl J, Mèszàros T, Bànhegyi G, Hunyadu L, Csala M. Endoplasmic reticulum: nutrient sensor in physiology and pathology. Trends Endocr Metab 2009; 20: 194-201.
14. Remmer H. Die Induktion arzneimittelabbauender Enzyme im endoplasmatischen Retikulum der Leberzelle durch Pharmaka. Dtsch Med Wochenschr 1967; 92: 2001-8.
15. Orrenius S. Further studies on the induction of the drughydroxylating enzyme system of liver microsomes. J Cell Biol 1965; 26: 725-33.
16. Conney AH. Pharmacological implications of microsomal enzyme induction. Pharmacol Revs 1967; 19: 317-66.
17. Luoma PV, Savolainen MJ, Sotaniemi EA, Pelkonen RO, Arranto AJ, Ehnholm C. Plasma high density lipoprotein and liver lipids and proteins in man. Relation to hepatic histology and microsomal enzyme induction.Acta Med Scand 1983; 214: 103-9.
18. Savolainen MJ, Arranto AJ, Hassinen IE, Luoma PV, Pelkonen RO, Sotaniemi EA. Relationship between lipid composition and drug metabolizing capacity of human liver. Eur J Clin Pharmacol 1985; 27: 727-32.
19. Luoma PV, Savolainen MJ, Sotaniemi EA, Arranto AJ, Pelkonen RO. Plasma HDL cholesterol and glucose in noninsulin- dependent diabetics related to liver lipids and micromal enzyme activity. Acta Med Scand 1985; 217: 473-479.
20. Karvonen I, Stengård JH, Huupponen R, Stenbäck FG, Sotaniemi EA. Effects of enzyme induction therapy on glucose and drug metabolism in obese mice model of non insulin dependent diabetes mellitus. Diabetes Res 1989; 10: 85-92.
21. Mitro N, Mak PA, Vargas L, et al. The nuclear receptor LXR is a glucose sensor. Nature 2007; 445: 219-23.
22. Orrenius S, Ericsson LE. On the relationship of liver glucose- 6 -phosphatase to the proliferation of endoplasmic reticulum in Phenobarbital induction. J Cell Biol 1966; 21: 243-256.
23. Karvonen I, Stengård JH, Saarni HU, Stenbäck F, Sotaniemi EA. Hepatic mixed function oxidase system and enzymatic glucose metabolism in rats. Diabetes Res 1987; 4: 195-200.
24. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Revs 2006; 58: 342-73.
25. Hoofnagle AN, Vaisar T, Mitra P. HDL lipids and insulin resistance.Curr Diab Rep 2010; 10: 78-86.
26. Tchoua U, Gillard BK, Pownall HJ. HDL superphospholipidation enhances key steps in reverse cholesterol transport. Atherosclerosis 2010; 209: 430-5.
27. Tontonoz P, Mangelsdorf DJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003; 17: 985-93.
28. Brewer BH Jr. HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease. Curr Cardiol Rep 2007; 9: 486-92.
29. Zarubica A, Trompier D, Chimini G. ABCA1, from pathology to membrane function. Pflugers Arch - Eur J Physiol 2007; 453: 569-79.
30. Björkhem I, Diczfalusy U. Oxysterols, friends, foes, or just fellow passengers. Arterioscler Thromb Vasc Biol 2002; 22: 734-42.
31. Luoma PV. Cytochrome P450 - physiological key factor against cholesterol accumulation and the atherosclerotic vascular process. Ann Med 2007; 39: 359-70.
32. Ross R. Atherosclerosis-an inflammatory disease. New Engl J Med 1999; 340: 115-26.
33. Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis; the role of oxidized phospholipids and HDL. J Lipid Res 2004; 45: 993-1006.
34. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nature Med 2003; 9: 213-9.
35. Mashima R, Yamamoto Y, Yoshimura S. Reduction of phosphatidylcholine hydroperoxide by apolipoprotein A-I: purification of the hydroperoxide-reducing proteins from human blood. J Lipid Res 1998; 39: 1133-40.
36. Yamamoto Y, Nagata Y, Niki E, Watanabe K, Yoshimura S. Plasma glutathione peroxidase reduces phosphatidylcholine hydroperoxide. Biochem Biophys Res Commun 1993; 193: 133-8.
37. Bisoendial RJ, Hovingh K, Levels JHM, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107: 2944-8.
38. Luoma PV, Rautio A, Stengård J, Sotaniemi EA, Marniemi J. High-density lipoprotein subfractions, apolipoproteins and antipyrine clearance in normal subjects. Eur J Clin Pharmacol 1990; 38: 625-7.
39. Xiao L, Xie X, Zhai Y. Functional crosstalk of CAR-LXR and ROR-LXR in drug metabolism and lipid metabolism. Adv Drug Deliv Rev 2010; 62: 1316-21.
40. Luoma PV, Sotaniemi EA, Arranto AJ. Serum LDL cholesterol, the LDL/HDL cholesterol ratio and liver microsomal enzyme induction evaluated by antipyrine kinetics. Scand J Clin Lab Invest 1983; 43: 671-5.
41. Miller M, Burgan RG, Osterlund L, Segrest JP, Garber DW. A prospective, randomized trial of phenytoin in nonepileptic subjects with reduced HDL cholesterol. Arterioscler Thromb Vasc Biol 1995; 15: 2151-6.
42. Luoma PV, Sotaniemi EA, Pelkonen RO, Savolainen MJ, Ehnholm C. Induction and lipoproteins. Lancet 1982; 1: 625.
43. Luoma PV, Arranto AJ, Ehnholm C, Sotaniemi EA. Liver histological changes and plasma high density lipoproteins in man. Res Commun Chem Pathol Pharmacol 1981; 33: 163-173.
44. Jacobs RL, Lingrell S, Zhao Y, Francis GA, Vance DE. Hepatic CTP:phosphocholine cytidylyltransferase-?? is a critical predictor of plasma high density lipoprotein and very low density lipoprotein. J Biol Chem 2008; 283: 2143-55.
45. Gehrig K, Lagace TA, Ridgway ND.Oxysterol activation of phosphatidylcholine synthesis involves CTP:phosphocholine cytidylyltransferase α translocation to the nucleus. Biochem J 2009; 418: 209-17.
46. Mäkelä SM, Jauhiainen M, Ala-Korpela M, et al. HDL2 of heavy alcohol drinkers enhances cholesterol efflux from raw macrophages via phospholipid- rich HDL2b particles. Alcoholism: Clin Exper Res 2008; 32: 991-1000.
47. Gelissen IC, Harris M, Rye KA, et al. ABCA1 and ABCG1 synergize to mediate cholesterol export to apoA-I. Arterioscler Thromb Vasc Biol 2006; 26: 534-40.
48. Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoAI/ lecithin discs increase pre-??-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 2001; 42: 1586-93.
49. Hsia SL, Duncan R, Schob AH, et al. Serum levels of highdensity lipoprotein phospholipids correlate with severity of angiographically defined coronary disease. Atherosclerosis 2000; 152: 469-73.
50. Luoma PV. Gene activation regresses atherosclerosis, promotes health, and enhances longevity. Lipids in Health and Disease 2010; 9: 67.
51. Walter M. Interrelationships among HDL metabolism, aging, and atherosclerosis. Arterioscler Thromb Vasc Biol 2009; 29: 1244-50.
52. Arai Y, Hirose N. Aging and HDL metabolism in elderly people more than 100 years old. J Atheroscler Thromb 2004; 11: 246-52.
53. Lahtela JT, Gachalyi B, Eksymä S, Hämäläinen A, Sotaniemi EA. The effect of enzyme inducing and inhibiting drugs on insulin mediated glucose metabolism in man. Br J Clin Pharmacol 1986; 21:19-26.
54. Lahtela JT, Arranto AJ, Stenbäck F, Sotaniemi EA. Insulinmediated glucose metabolism is related to liver structure and microsomal function. Scand J Gastroent 1986; 21: 737-43.
55. Laffitte BA, Mangelsdorf DJ, Tontonoz P. Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue. PNAS 2003; 100: 5419-24.
56. Luchsinger JA, Gustafson DR. Adiposity, type 2 diabetes and Alzheimer's disease. J Alzheimers Dis 2009; 16: 693-704.
57. Garner B. Lipids and Alzheimer's disease. Biochim Biophys Acta 2010; 1801; 747-9.
58. Ricobaraza A, Cuadrado-Tejedor M, Pères-Mediavilla A, Frechilla D, Del Rio J, Garcia-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tay pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009; 34: 1721-32.
59. Wang I, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. Lipid X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. PNAS 2002; 99: 13878-83.
60. Hirsch-Reinshagen V, Burgess BL, Wellington CL. Why lipids are important for Alzheimer disease. Mol Cell Biochem 2009; 326: 121-9.
61. Fan J, Donkin J, Wellington C. Greasing the wheels of Aβ clearance in Alzheimer's disease: The role of lipids and apolipoprotein E. Biofactors 2009; 35: 239-48.
62. Hartz AMS, Miller DS, Bauer B. Restoring blood-brain barrier P-glycoprotein reduces brain amyloid-?? in a mouse model of Alzheimer's disease. Mol Pharmacol 2010; 77: 715-23.
63. Singh-Manoux A, Gimeno D, Kivimaki M, Brunner E, Marmot MG. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife. Arterioscler Thromb Vasc Biol 2008; 28: 1556-62.
64. Atzmon G, Gabriely I, Greiner W, Davidson D, Schechter B, Barzilai N. Plasma HDL levels correlate with cognitive function in exceptional longevity. J Gerontol Med Sci 2002; 57A: M712-5.
65. Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia. Arch Neurol 2009; 66: 300-5.
66. Björkhem I. Crossing the barrier: oxysterols as cholesterol transporters and metabolic modulators in the brain. J Intern Med 2006; 260: 493-508.
67. Papassotiropoulos A, Streffer JR, Tsolaki M, et al. Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with intronic CYP46 polymorphism. Arch Neurol 2003; 60: 29-35.
68. Hotamisligil GS. Endoplasmic reticulum stress and atherosclerosis. Nature Med 2010; 16: 396-9.
69. Özcan U, Cao Q, Yilmaz E, et al. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 2004; 306: 457-61.
70. Engin F, Hotamisligil GS. Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic disease. Diabetes Obes Metab 2010; 12 (Suppl 2) 108-15.
71. Schuck S, Prinz WA, Thorn KS, Voss C, Walter P. Membrane expansion alleviates endoplasmic reticulum stress independently of the unfolded protein response. J Cell Biol 2009; 187: 525-36.
72. Sciburi R, Bommiasamy, H, Buldak GL, et al. Coordinate regulation of phospholipid biosynthesis and secretory pathway gene expression in XBP-1 (S)-induced endoplasmic reticulum biogenesis. J Biol Chem 2007; 282:7024-34.
73. Erbay E, Babaev VR, Mayers JR, et al. Reducing endoplasmic reticulum stress through a macrophage lipid chaperone alleviates atherosclerosis. Nat Med 2009; 15: 1383-91.
74. Gregor MF, Yang L, Fabbrini E, et al. Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss. Diabetes 2009; 58: 693-700.
75. Özcan U, Ylimaz E, Özcan L, et al. Chemical chaperones reduce ER stress and restore glucose homeostais in a mouse model of type 2 diabetes. Science. 2006; 313: 1137-1140.
76. Kars M, Yang L, Gregor MF, et al. Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes 2010; 59: 1899-905.
77. Kim EJ, Um SJ. SIRT1: roles in aging and cancer. BMB Reports 2008; 41: 751-6.
78. Rodgers JT, Puigserver P. Fasting -dependent glucose and lipid metabolic response through hepatic sirtuin 1. PNAS 2007; 104: 12861-6.
79. Feige JM, Auwerx J. DisSirting on LXR and cholesterol metabolism. Cell Metab 2007; 6: 343-5.
80. Dullens, SPJ, Plat J, Mensink RP. Increasing apoA-I production as a target for CHD risk reduction Nutrition Metab & Cardiovasc Dis 2007; 17; 618-28.
81. Lamon-Fava S, Diffenderfer MR, Barrett PHR, et al. Extended - release niacin alters the metabolism of plasma apoliprotein (apo) A-I and apo-B containing lipoproteins. Arterioscler Thromb Vasc Biol 2008; 28: 1672-8.
82. Hofman MK, Weggemans RM, Zock PL, Schouten EG, Katan MB, Princen HMG. CYP7A1 A-278C polymorphism affects the response of plasma lipids after dietary cholesterol or cafesterol interventions in humans. J Nutr 2004; 134: 2200-4.
83. Gao J. The constitutive androstane receptor is an antiobesity nuclear receptor that improves insulin sensitivity. J Biol Chem 2009; 284: 25984-92.
84. Dong B, Saha PK, Huang W, et al. Activation of nuclear receptor CAR ameliorates diabetes and fatty liver disease. PNAS 2009; 106: 18831-6.
85. Stampfer MJ. Cardiovascular disease and Alzheimer's disease: common links. J Intern Med 2006; 260: 211-23.
86. Estruch R, Martinez-Gonzalez MA, Corella D, et al. Effects of a Mediterranien-style diet on cardiovascular risk factors. A randomized trial. Ann Intern Med 2006; 145: 1-11.
87. Scarmeas N, Luchsinger JA, Schupf N, Brickman AM, Cosentino S, Tang MX. Physical activity, diet, and risk of Alzheimer disease. JAMA 2010; 302: 627-37.
88. Jimènez-Gomèz J, Marin C, Pèrez-Martinèz P, et al. A lowfat, high-complex carbohydrate diet supplemented with longchain[n-3] fatty acids alters the postprandial lipoprotein profile in patients with metabolic syndrome. J Nutr 2010; 140: 1595-1601.
89. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diab Care 1997; 20: 537-44.
90. Geda YE, Roberts RO, Knopman DS, et al. Physical exercise, aging, and mild cognitive impairment. Arch Neurol 2010; 67: 80-6.
91. Torres TP, Catlin RL, Chan R, et al. Restoration of hepatic glucokinase expression corrects hepatic glucose flux and normalizes plasma glucose in Zucker diabetic fatty rats. Diabetes 2009; 58: 78-86.
92. Sonoda J, Pei L, Evans RM. Nuclear receptors: Decoding metabolic disease. FEBS Lett 2008; 582: 2-9.
93. Handschin C, Meyer UA. Regulatory network of lipid-sensing nuclear receptors: roles of CAR, PXR, LXR, and FXR. Arch Biochem Biophys 2005; 433: 387-96.
94. Commerford RS, Vargas L, Dorfman SE, et al. Dissection of the insulin-sensitizing effect of liver X receptor ligands. Mol Endocrinol 2007; 21: 3002-12.
95. Paumelle R, Staels B. Peroxisome prolifertor-activated receptors mediate pleiotrophic actions of statins. Circ Res 2007; 100: 1394-5.
96. Kliewer SA. Cholesterol detoxification by nuclear pregnane X receptor. PNAS 2005; 102: 2675-6.
97. Claudel T, Staels B, Kuipers F. The farnesoid X receptor - a molecular link between bile acid and lipid and glucose metabolism. Arterioscler Thromb Vasc Biol 2005; 25: 2020-2030.
98. Sierra F, Hadley E, Suzman R, Hodes R. Prospects of life span extension. Annu Rev Med 2009; 60: 457-69.
99. Willcox BJ, He Q, Chen R, et al. Midlife risk factors and healthy survival in man. JAMA 2006; 296: 2343-50.
100. Middleton LE, Yaffe K. Promising strategies for the prevention of dementia. Arch Neurol 2009; 66: 1210-15.
101. Wendell CR, Zonderman AB, Metter JM, Najjar SS, Wadstein SR. Carotid intimal medial thickness predicts cognitive decline among adults without clinical vascular disease. Stroke 2009; 40: 3180-5.
102. Dolan H, Crain B, Troncoso J, Resnick SM, Zonderman AB, Obrien RJ. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore longitudinal study of aging cohort. Ann Neurol 2010; 68: 231-40.